EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)

Cameron R Wolfe iD, Jonathan Cohen, Kathryn Mahoney, Anna Holmes, Natalia Betancourt, Deepali Gupta, Kazima Tosh, Kristin Narayan, Ed Campanaro, Chloe Katz, Anne-Marie Phelan, Ilker Yalcin und 5 weitere

Clinical Infectious Diseases · 06.10.2025 · 81 (3) · 439-450

DOI: 10.1093/cid/ciaf265 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 24.05.2025. Verfasst von Cameron R Wolfe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, COVID-19, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Invivyd, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We report an interim analysis of safety and efficacy of pemivibart in individuals with (cohort A) or without (cohort B) significant immunocompromise in the phase 3 CANOPY trial.

Methods

Eligible participants (aged ≥18 years; negative for current severe acute respiratory syndrome coronavirus 2 infection) received 2 intravenous 4500-mg pemivibart infusions (cohort A) or were randomized 2:1 to receive blinded pemivibart or placebo infusions (cohort B) 90 days apart. Safety was a primary end point for both cohorts. The primary immunobridging end point for cohort A has been reported elsewhere. Composite incidence of reverse-transcription polymerase chain reaction–confirmed symptomatic coronavirus disease 2019 (COVID-19), COVID-19 hospitalization, and all-cause mortality was an exploratory end point.

Results

In September–November 2023, 306 participants received pemivibart (cohort A), and 317 received pemivibart and 162 placebo (cohort B). The most common study drug–related adverse events were infusion-related reactions (cohort A: 11 of 306 [3.6%]; cohort B: 7 of 317 [2.2%] for pemivibart and 0 of 162 for placebo). Four of 623 participants (0.6%) who received pemivibart experienced anaphylactic reactions (serious in 2). In cohort A, the composite COVID-19 incidence through month 6 was 11 of 298 (3.7%; 2 deaths). In cohort B, 6 of 317 pemivibart (1.9%; no deaths) and 19 of 160 placebo (11.9%; no deaths) recipients met the end point through month 6 (84.1% standardized relative risk reduction [95% confidence interval, 60.9–93.5; nominal P < .001]), and 15 of 317 pemivibart (4.7%; 1 death) and 29 of 160 placebo (18.1%; no deaths) recipients met the end point through month 12 (73.9% standardized relative risk reduction [52.8–85.6; nominal P < .001]). Twelve-month protection was conferred with no additional dosing.

Conclusions

Pemivibart provided prophylactic efficacy against COVID-19 and was well tolerated by most participants. Anaphylaxis was an important safety risk. Clinical Trials Registration NCT06039449

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentCOVID-19Antibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAgedAdultSARS-CoV-2Treatment OutcomeDouble-Blind Method

Stichwörter der Autor:innen

COVID-19VYD222immunocompromisedmonoclonal antibodypemivibart

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA.
  • Jadestone Clinical Research, Silver Spring, Maryland, USA.
  • Invivyd, Inc, Waltham, Massachusetts, USA.

ORCID-Profile: Cameron R Wolfe, Pete Schmidt

Förderung

  • Invivyd, Inc

Zitieren

APA

Wolfe, C. R., Cohen, J., Mahoney, K., Holmes, A., Betancourt, N., Gupta, D., Tosh, K., Narayan, K., Campanaro, E., Katz, C., Phelan, A. M., Yalcin, I., Wingertzahn, M., Hawn, P., Schmidt, P., Li, Y., & Popejoy, M. (2025). Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical Infectious Diseases, 81(3), 439-450. https://doi.org/10.1093/cid/ciaf265

Vancouver

Wolfe CR, Cohen J, Mahoney K, Holmes A, Betancourt N, Gupta D, et al. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical Infectious Diseases. 2025;81(3):439-450. doi:10.1093/cid/ciaf265

BibTeX
@article{Wolfe2025,
  author = {Wolfe, Cameron R and Cohen, Jonathan and Mahoney, Kathryn and Holmes, Anna and Betancourt, Natalia and Gupta, Deepali and Tosh, Kazima and Narayan, Kristin and Campanaro, Ed and Katz, Chloe and Phelan, Anne-Marie and Yalcin, Ilker and Wingertzahn, Mark and Hawn, Pamela and Schmidt, Pete and Li, Yong and Popejoy, Myra},
  title = {Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {3},
  pages = {439--450},
  doi = {10.1093/cid/ciaf265}
}
Kostenlos starten →